Sernova Corp T.SVA

Alternate Symbol(s): SEOVF

Healthcare Biotechnology

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

TSX:SVA - Post by User

Sernova Corp > any thoughts

<< Previous

Bullboard Posts

Next >>

Comment by elgin1on Jun 01, 2021 2:28pm

129 Views

Post# 33304211

RE:RE:RE:any thoughts

elgin1 wrote:

BioTeck wrote: I think that infections are quite common when doing any kind of surgery with severe diabetics. When you add immunosuppression to the equation it makes it even easier. When you count all the people and the number of incisions required, 1 isn't a big deal in my opinion. Remember these are the diabetics who get infections by just living and have to get toes cut off due to gangren etc. THere are a couple of things to consider.

1. There 0 severe hypoglycemic episodes
2. 25-40 percent reduction in insulin
3. Reduction in body weight.

Even if this requires portal vein top ups, those injections require far fewer islets than the edmonton protocol. So instead of 1 patient requiring up to 2 donor livers, this is a game changer even if it's just to use in conjunction with the Edmonton protocol. Ive aleays thought that diabetes would be a hard one to cure and think it's just bonus. Hypo/Hemo is where there are much greater chances for success.

We will wait to see what Witkowski thinks.

Bio,

I agree about the infections with diabetetics , that it is imperative that immune coating technology is advanced as quickly as possible to avoid use of immunosuppresion in highly compromised diabetics.

We don't have much detail about the clinical trial , but I was hoping to top up via portal vein. I guess we will see what the exact protocol and results will be by the end of the month.

Still not a lot of liquidity to move a position imo.

Elgin